Physician
Kalantari, Gita
Kalantari, Gita was paid $6.08M by Medicaid between Jan 2018 and Aug 2023, across 73 billing codes. Its largest line is J7307, Etonogestrel (contraceptive) implant system, including implant and supplies — 18% of everything it billed.
33Billing provider infoKALANTARI, GITA
LONG BEACH, CA 90813
LONG BEACH, CA 90813
33aNPI1790968659assigned 12/13/2007
33bProvider typeFamily Medicine Physician
28Total paid$6.08M
24GClaims155,292
24DCodes billed73
24AFirst – last monthJan 2018 – Aug 2023
Compared with peers
Next to other Family Medicine Physician providers in California
Rank by total paid#61 of 2,511
Median peer was paid$13K
This provider vs. median473×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,992 | $1.72M | |
| 2019 | 38,762 | $1.53M | |
| 2020 | 24,068 | $1.04M | |
| 2021 | 27,141 | $1.01M | |
| 2022 | 18,833 | $594K | |
| 2023 | 5,496 | $194K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 18% | 1,318 | 1,284 | $1.07M |
| S4993 | Contraceptive pills for birth control | 12% | 4,222 | 4,177 | $728K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 9.7% | 14,523 | 14,344 | $590K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 9.5% | 14,488 | 14,313 | $577K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.5% | 9,247 | 8,328 | $519K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.4% | 16,124 | 13,747 | $511K |
| S0199 | Medically induced abortion by oral ingestion of medication including all associated services and supplies (e.g., patient counseling, office visits, confirmation of pregnancy by hcg, ultrasound to confirm duration of pregnancy, ultrasound to confirm completion of abortion) except drugs | 3.8% | 417 | 414 | $233K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 3.7% | 3,301 | 3,214 | $227K |
| 90651 | 2.9% | 832 | 816 | $175K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 2.7% | 2,047 | 1,883 | $161K |
| J3490 | Unclassified drugs | 2.2% | 5,254 | 5,044 | $135K |
| J7304 | Contraceptive supply, hormone containing patch, each | 2.0% | 119 | 118 | $122K |
61 more codes
| A4267 | Contraceptive supply, condom, male, each | 1.9% | 10,243 | $117K |
| 11981 | 1.7% | 553 | $102K | |
| 87806 | 1.6% | 4,216 | $95K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.2% | 2,860 | $75K |
| 99203 | Doctor's office visit, new patient (routine) | 1.1% | 1,089 | $69K |
| 58300 | <1% | 557 | $51K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 629 | $49K |
| 90674 | <1% | 1,612 | $48K | |
| 81025 | <1% | 16,474 | $45K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,534 | $42K |
| 11976 | <1% | 702 | $40K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 1,865 | $39K |
| 96156 | <1% | 608 | $38K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 314 | $35K |
| J7300 | Intrauterine copper contraceptive (paragard) | <1% | 35 | $20K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 472 | $20K |
| S0190 | Mifepristone, oral, 200 mg | <1% | 437 | $19K |
| 90715 | <1% | 396 | $18K | |
| 99385 | <1% | 340 | $17K | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 3,408 | $14K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 649 | $13K |
| 83986 | <1% | 3,410 | $11K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 12 | $9K |
| 99000 | <1% | 3,336 | $8K | |
| 58301 | <1% | 222 | $6K | |
| J7303 | Contraceptive supply, hormone containing vaginal ring, each | <1% | 31 | $6K |
| 96150 | <1% | 615 | $6K | |
| 57454 | <1% | 56 | $4K | |
| 81002 | <1% | 1,945 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,215 | $2K |
| 59425 | <1% | 28 | $2K | |
| 96151 | <1% | 248 | $2K | |
| 86580 | <1% | 154 | $1K | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 254 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 218 | $1K |
| S0191 | Misoprostol, oral, 200 mcg | <1% | 438 | $885.62 |
| 85018 | <1% | 619 | $790.50 | |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | <1% | 428 | $629.21 |
| 87430 | <1% | 50 | $529.13 | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 32 | $454.14 |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 216 | $441.67 |
| 96127 | <1% | 155 | $422.72 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 301 | $349.16 |
| 86901 | <1% | 26 | $48.98 | |
| S5000 | Prescription drug, generic | <1% | 2,349 | $26.08 |
| S5001 | Prescription drug, brand name | <1% | 362 | $2.00 |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 796 | $0.78 |
| 1160F | 0% | 2,393 | $0.00 | |
| 1159F | 0% | 2,393 | $0.00 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 719 | $0.00 |
| 3078F | 0% | 1,879 | $0.00 | |
| G8783 | Normal blood pressure reading documented, follow-up not required | 0% | 1,598 | $0.00 |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 0% | 117 | $0.00 |
| 4004F | 0% | 72 | $0.00 | |
| 99442 | 0% | 40 | $0.00 | |
| 1036F | 0% | 2,062 | $0.00 | |
| 3074F | 0% | 1,946 | $0.00 | |
| 2000F | 0% | 815 | $0.00 | |
| 3008F | 0% | 403 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 442 | $0.00 |
| 99441 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.